NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the cas ...

NEW YORK, April 19, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the cas ...

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud that negatively impacted investors between August 8, 2024, and February 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying its significance as a "minor headwind" [2] - Following the announcement of disappointing financial results for Q4 and fiscal year 2024, Viatris' stock price dropped from $11.24 to $9.53 per share, a decline of approximately 15.21% in one day [2] Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

PHILADELPHIA, April 17, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired VIATRIS securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff representati ...

NEW ORLEANS, April 17, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvan ...

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=143351&from=4CLASS PERIOD: August 8, 2024 to Februar ...

SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give ...

Class Period: May 30, 2024 - February 6, 2025 Lead Plaintiff Deadline: June 3, 2025 The Complaint alleges that Defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Specifically, the Complaint alleges that Defendants' statements misrepresented the FDA's issuance of a warning letter and its impact on Viatris' operations and that Defendants routinely referred to the impact of the warning letter as a mere "minor headwind" for the Company. F ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Viatris Inc. securities during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between August 8, 2024, and February 26, 2025, and aims to address misleading information provided by Viatris regarding the failed inspection of its Indore, India facility [1][4]. - Defendants allegedly downplayed the impact of an FDA Warning Letter, which restricted the shipment of eleven products from the Indore facility, referring to it as a "minor headwind" [4][6]. - The lawsuit claims that Viatris did not disclose critical information about the inspection timeline, remediation efforts, and the financial implications of the Warning Letter, leading to artificially inflated stock prices for investors [5][6]. Group 2: Investor Actions - Investors who purchased Viatris securities during the Class Period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly, with a deadline to serve as lead plaintiff set for June 3, 2025 [3][8]. - It is noted that no class has been certified yet, and investors have the option to select their counsel or remain absent from the class [9].

Core Viewpoint - The Viatris class action lawsuit alleges that the company and its executives misrepresented the impact of regulatory issues on its financial outlook, leading to significant stock price declines following disappointing earnings guidance [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Quinn v. Viatris Inc., and it involves purchasers of Viatris securities from August 8, 2024, to February 26, 2025, with a deadline of June 3, 2025, for lead plaintiff applications [1]. - The lawsuit claims that Viatris downplayed the ramifications of a failed FDA inspection at its Indore facility, which significantly affected its revenue outlook and growth projections [3]. - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024, Viatris' stock price dropped by over 15% on February 27, 2025 [4]. Group 2: Company Background - Viatris is described as a global healthcare company facing challenges related to regulatory compliance and product manufacturing [2]. - The law firm Robbins Geller Rudman & Dowd LLP, which is leading the class action, has a strong track record in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].